{"disease":{"id":"atherosclerotic-cardiovascular-disease","name":"Atherosclerotic cardiovascular disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":9},"drugs":{"marketed":[{"drug_id":"inclisiran","indication_name":"Atherosclerotic cardiovascular disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leqvio","generic_name":"INCLISIRAN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Proprotein convertase subtilisin/kexin type 9","drug_class":"","quality_score":59,"revenue":"863","mechanism":"Leqvio works by binding to PCSK9, preventing it from breaking down LDL receptors."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07141914","title":"A Master Protocol for Semaglutide Effects on Cardiovascular and Obesity-related Outcomes in People With Overweight or Obesity in the Real World","phase":"","overall_status":"COMPLETED","enrollment_count":285327,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05974345","title":"In Silico Study Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Patients With Established Cardiovascular Disease","phase":"","overall_status":"COMPLETED","enrollment_count":204691,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT07203677","title":"Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)","phase":"","overall_status":"COMPLETED","enrollment_count":49065,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06874751","title":"Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World","phase":"","overall_status":"COMPLETED","enrollment_count":45456,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05378529","title":"A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)","phase":"NA","overall_status":"COMPLETED","enrollment_count":39480,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07023445","title":"Patterns of Inclisiran Use in the Real World: An Analysis of US Databases","phase":"","overall_status":"COMPLETED","enrollment_count":37688,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05030428","title":"Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":17004,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05739383","title":"A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14012,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT02104817","title":"Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13078,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07037433","title":"Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":12800,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT07196280","title":"Protective Effect of 5-Alpha Reductase Inhibitors on Atherosclerotic Cardiovascular Disease in Populations With BPH: Evidence From UK Biobank Cohort and Chinese Single Center Database Studies","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT04271280","title":"Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events","phase":"","overall_status":"COMPLETED","enrollment_count":9559,"lead_sponsor_name":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","has_results":true},{"nct_id":"NCT05581303","title":"Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":7297,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT06295679","title":"A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease","phase":"","overall_status":"RECRUITING","enrollment_count":7000,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT03225196","title":"Extracellular RNAs in Relation to Cardiometabolic Risk","phase":"","overall_status":"COMPLETED","enrollment_count":4495,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT05765370","title":"LDL Cholesterol TARGETs in OLDer Patients (Age≥75 Years) With ASCVD (TARGET OLD)","phase":"NA","overall_status":"RECRUITING","enrollment_count":4200,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT07363980","title":"Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":4000,"lead_sponsor_name":"Ellen Margrethe Hauge","has_results":false},{"nct_id":"NCT04626973","title":"Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":3048,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT06541691","title":"Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Rajaie Cardiovascular Medical and Research Center","has_results":false},{"nct_id":"NCT04394715","title":"Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID)","phase":"NA","overall_status":"COMPLETED","enrollment_count":2596,"lead_sponsor_name":"Yale University","has_results":true},{"nct_id":"NCT05142722","title":"Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2530,"lead_sponsor_name":"NewAmsterdam Pharma","has_results":true},{"nct_id":"NCT06858332","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","phase":"","overall_status":"RECRUITING","enrollment_count":2382,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05485961","title":"Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":2310,"lead_sponsor_name":"CSL Behring","has_results":false},{"nct_id":"NCT02666664","title":"Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2230,"lead_sponsor_name":"Esperion Therapeutics, Inc.","has_results":true},{"nct_id":"NCT05749874","title":"Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2024,"lead_sponsor_name":"China National Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT03911284","title":"The Learning Registry","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT06494501","title":"The Prevent Coronary Artery Disease Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT06589791","title":"A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists","phase":"","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT03067441","title":"Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1462,"lead_sponsor_name":"Esperion Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06871514","title":"Effectiveness of Decision Support for Cardiovascular Risk Management in People With Cardiovascular Disease","phase":"NA","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"dr.Frank L.J. Visseren","has_results":false},{"nct_id":"NCT03911141","title":"Behavioral Economic Approaches to Increase Physical Activity Among Patients With Elevated Risk for Cardiovascular Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":1062,"lead_sponsor_name":"University of Pennsylvania","has_results":true},{"nct_id":"NCT05629767","title":"Tracking of Lipid Lowering Therapy in Jordan","phase":"","overall_status":"TERMINATED","enrollment_count":1000,"lead_sponsor_name":"Jordan Collaborating Cardiology Group","has_results":false},{"nct_id":"NCT05724615","title":"Default Bulk Ordering and Text Messaging to Enhance Outreach for Lipid Screening (Missing Lipids)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT07520643","title":"MISTIC Study: Atherosclerosis, Neurocognition & Cardiovascular Signaling","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT04807400","title":"Study in Primary Care Evaluating Inclisiran Delivery Implementation + Enhanced Support","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":892,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05659888","title":"Real Life Lipid Management in Hospitals Not Participating in PENELOPE Trial - Control Population for PENELOPE","phase":"","overall_status":"COMPLETED","enrollment_count":827,"lead_sponsor_name":"Clinical Operations WCN B.V.","has_results":false},{"nct_id":"NCT02991118","title":"Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":779,"lead_sponsor_name":"Esperion Therapeutics, Inc.","has_results":true},{"nct_id":"NCT07208331","title":"Evaluation of an Integrated, Digital, Nurse-led, Remote Monitoring Care Pathway for Cardiovascular Risk Management","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05976893","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":620,"lead_sponsor_name":"Xiang Xie","has_results":false},{"nct_id":"NCT07160829","title":"Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management","phase":"","overall_status":"COMPLETED","enrollment_count":608,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT05755373","title":"A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists","phase":"","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Novo Nordisk A/S","has_results":false},{"nct_id":"NCT06960902","title":"Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study)","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT04924686","title":"Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Zhujiang Hospital","has_results":false},{"nct_id":"NCT05726838","title":"The Belgian REAL (BE.REAL) Registry","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT06875973","title":"Pelacarsen Roll-over Extension Program","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":599,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03749473","title":"Evaluation of the Novel Use of Gamification With Alternative Goal-setting Experiences","phase":"NA","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06471803","title":"Multi-omics Merge for Ensemble Subtyping for Atherosclerotic Cardiovascular Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Henan Province Clinical Research Center for Cardiovascular Diseases","has_results":false},{"nct_id":"NCT04929249","title":"A Randomized Study to Evaluate the Effect of an \"Inclisiran First\" Implementation Strategy Compared to Usual Care in Patients With Atherosclerotic Cardiovascular Disease and Elevated LDL-C Despite Receiving Maximally Tolerated Statin Therapy (VICTORION-INITIATE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06267560","title":"Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":422,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05409716","title":"Compressive Elastic Dressing Versus TR Band","phase":"NA","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"An-Najah National University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}